Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

In hospitalised patients with Covid-19 (n=389), the addition of tocilizumab to standard care reduced the likelihood of progression to mechanical ventilation or death by 28 days (12.0% v 19.3%; HR 0.56; 95% CI 0.33-0.97; p=0.04) but did not improve overall survival.

Source:

New England Journal of Medicine